Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02920021 · ClinicalTrials.gov registry record · Phase 2
Study to Investigate Etokimab (ANB020) Activity in Adult Participants With Peanut Allergy
A Phase 2 study, sponsored by AnaptysBio.
- Completed
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
NCT02920021 is a Phase 2 study that has completed, run by AnaptysBio. The registered enrollment target is 20 participants.
The verdict
NCT02920021, a Phase 2 study, has completed, sponsored by AnaptysBio.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
Study Summary
The purpose of this study is to determine etokimab safety, tolerability and activity in adult participants with peanut allergy.
Interventions
- DRUG Placebo
- DRUG Etokimab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2017-01-26 |
| Est. Completion | 2018-03-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02920021
The ClinicalTrials.gov registry entry for NCT02920021 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AnaptysBio, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02920021 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02920021 about?
NCT02920021 is a clinical study titled "Study to Investigate Etokimab (ANB020) Activity in Adult Participants With Peanut Allergy". The purpose of this study is to determine etokimab safety, tolerability and activity in adult participants with peanut allergy.
What is the current status of trial NCT02920021?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2017-01-26. Estimated completion is 2018-03-30.
What interventions are being tested in trial NCT02920021?
The interventions under investigation include: Placebo (DRUG), Etokimab (DRUG).
Who is sponsoring clinical trial NCT02920021?
This trial is sponsored by AnaptysBio, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.